{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:08:04Z","timestamp":1789614484766,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The safety and efficacy of landiolol have not been fully elucidated in pediatric patients. This study aimed to clarify the safety and efficacy of landiolol in a pediatric cohort. We retrospectively assessed the clinical features of 21 pediatric patients who were administered landiolol at our hospital. We also investigated the rates of sinus rhythm conversion and heart rate response. The median patient age was 7\u00a0months (interquartile range 1\u201313\u00a0months). The etiology of tachyarrhythmia was junctional ectopic tachycardia in 10 patients (47.6%), atrial tachycardia in 10 patients (47.6%), and ventricular tachycardia in 1 patient (4.8%). Of the 21 children, 18 (85.7%) had congenital heart defects, including 14 (77.8%) in whom a landiolol infusion was performed perioperatively. The landiolol infusion was effective in 18 pediatric patients (85.7%), as measured by the conversion to sinus rhythm or a reduced heart rate. Atrial tachycardia in the perioperative period was terminated in all patients. Of 7 patients with tachyarrhythmias unrelated to the perioperative period, landiolol was effective in 5. No adverse effects were reported in any patient. Landiolol infusion is effective and safe in pediatric patients with tachyarrhythmia of various etiologies, especially those with atrial tachyarrhythmia during the perioperative period.<\/jats:p>","DOI":"10.1007\/s00246-021-02653-7","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T03:04:57Z","timestamp":1623035097000},"page":"1700-1705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and Efficacy of Landiolol Hydrochloride in Children with Tachyarrhythmia of Various Etiologies"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7186-1145","authenticated-orcid":false,"given":"Atsuko","family":"Ashida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyasu","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Odanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"2653_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(20)30037-0","volume":"8","author":"Y Kakihana","year":"2020","unstructured":"Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, Yamada Y, Nagano T, Morishima E, Matsuda N, on behalf of the J-Land 3S Study Group (2020) Efficacy and safety of landiolol, an ultra-short-acting \u03b21-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med 8:863\u2013872. https:\/\/doi.org\/10.1016\/S2213-2600(20)30037-0","journal-title":"Lancet Respir Med"},{"key":"2653_CR2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1253\/circj.CJ-12-1618","volume":"77","author":"R Nagai","year":"2013","unstructured":"Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M, Okamura T, Hori M, J Land Investigators (2013) Urgent management of rapid heart rate in patients with atrial fibrillation\/flutter and left ventricular dysfunction: comparison of the ultra-short-acting \u03b21-selective blocker landiolol with digoxin (J-Land Study). Circ J 77:908\u2013916. https:\/\/doi.org\/10.1253\/circj.CJ-12-1618","journal-title":"Circ J"},{"key":"2653_CR3","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/europace\/eut044","volume":"15","author":"H Saiki","year":"2013","unstructured":"Saiki H, Nakagawa R, Ishido H, Masutani S, Senzaki H (2013) Landiolol hydrochloride infusion for treatment of junctional ectopic tachycardia in post-operative paediatric patients with congenital heart defect. Europace 15:1298\u20131303. https:\/\/doi.org\/10.1093\/europace\/eut044","journal-title":"Europace"},{"key":"2653_CR4","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.athoracsur.2013.01.057","volume":"95","author":"C Tokunaga","year":"2013","unstructured":"Tokunaga C, Hiramatsu Y, Kanemoto S, Takahashi-Igari M, Abe M, Horigome H, Sakakibara Y (2013) Effects of landiolol hydrochloride on intractable tachyarrhythmia after pediatric cardiac surgery. Ann Thorac Surg 95:1685\u20131688. https:\/\/doi.org\/10.1016\/j.athoracsur.2013.01.057","journal-title":"Ann Thorac Surg"},{"key":"2653_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/PCC.0000000000001573","volume":"19","author":"F Yoneyama","year":"2018","unstructured":"Yoneyama F, Tokunaga C, Kato H, Nakajima T, Mathis BJ, Sakamoto H, Hiramatsu Y (2018) Landiolol hydrochloride rapidly controls junctional ectopic tachycardia after pediatric heart surgery. Pediatr Crit Care Med 19:713\u2013717. https:\/\/doi.org\/10.1097\/PCC.0000000000001573","journal-title":"Pediatr Crit Care Med"},{"key":"2653_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s11748-012-0141-0","volume":"61","author":"T Hasegawa","year":"2013","unstructured":"Hasegawa T, Oshima Y, Maruo A, Matsuhisa H, Kadowaki T, Noda R (2013) Landiolol for junctional ectopic tachycardia refractory to amiodarone after pediatric cardiac surgery. Gen Thorac Cardiovasc Surg 61:350\u2013352. https:\/\/doi.org\/10.1007\/s11748-012-0141-0","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"2653_CR7","first-page":"601","volume":"31","author":"Y Maehata","year":"2011","unstructured":"Maehata Y, Nishigaki K, Kawahira Y, Yanase G, Sugita R (2011) The efficacy of landiolol against junctional ectopic tachycardia after pediatric cardiac surgery\u2014a novel treatment of ultra\u2014short\u2014acting beta\u2014adrenergic blocker in congenital heart disease\u2014report of two cases. Prog Med 31:601\u2013604","journal-title":"Prog Med"},{"key":"2653_CR8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/ped.13261","volume":"59","author":"S Fujita","year":"2017","unstructured":"Fujita S, Futatani T, Kubo T, Itamochi M, Yachi Y, Iwasaki H, Shimao A, Ina S, Higashiyama H, Igarashi N, Hatasaki K (2017) Virus myocarditis in a 1-month-old boy presenting as two types of paroxysmal supraventricular tachycardia. Pediatr Int 59:627\u2013632. https:\/\/doi.org\/10.1111\/ped.13261","journal-title":"Pediatr Int"},{"key":"2653_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1017\/S1047951115000244","volume":"26","author":"H Oka","year":"2016","unstructured":"Oka H, Sugimoto M, Azuma H (2016) Efficacy of landiolol for the treatment of junctional ectopic tachycardia resulting from sepsis. Cardiol Young 26:183\u2013187. https:\/\/doi.org\/10.1017\/S1047951115000244","journal-title":"Cardiol Young"},{"key":"2653_CR10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S0022-5223(19)40133-5","volume":"71","author":"C-K Tan","year":"1976","unstructured":"Tan C-K, Glisson SN, El-Etr AA, Ramakrishnaiah KB (1976) Levels of circulating norepinephrine and epinephrine before, during, and after cardiopulmonary bypass in man. J Thorac Cardiovasc Surg 71:928\u2013931. https:\/\/doi.org\/10.1016\/S0022-5223(19)40133-5","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2653_CR11","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1248\/cpb.40.1462","volume":"40","author":"S Iguchi","year":"1992","unstructured":"Iguchi S, Iwamura H, Nishizaki M, Hayashi A, Senokuchi K, Kobayashi K, Sakaki K, Hachiya K, Ichioka Y, Kawamura M (1992) Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101. Chem Pharm Bull 40:1462\u20131469. https:\/\/doi.org\/10.1248\/cpb.40.1462","journal-title":"Chem Pharm Bull"},{"key":"2653_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2133\/dmpk.20.337","volume":"20","author":"M Murakami","year":"2005","unstructured":"Murakami M, Furuie H, Matsuguma K, Wanibuchi A, Kikawa S, Irie S (2005) Pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra short-acting beta1-selective blocker, in a dose escalation regimen in healthy male volunteers. Drug Metab Pharmacokinet 20:337\u2013344. https:\/\/doi.org\/10.2133\/dmpk.20.337","journal-title":"Drug Metab Pharmacokinet"},{"key":"2653_CR13","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/clpt.1991.78","volume":"49","author":"DB Wiest","year":"1991","unstructured":"Wiest DB, Trippel DL, Gillette PC, Garner SS (1991) Pharmacokinetics of esmolol in children. Clin Pharmacol Ther 49:618\u2013623. https:\/\/doi.org\/10.1038\/clpt.1991.78","journal-title":"Clin Pharmacol Ther"},{"key":"2653_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1213\/ANE.0b013e3182025af7","volume":"112","author":"SK Yu","year":"2011","unstructured":"Yu SK, Tait G, Karkouti K, Wijeysundera D, McCluskey S, Beattie WS, Stuart McCluskey W, Beattie S (2011) The safety of perioperative esmolol: a systematic review and meta-analysis of randomized controlled trials. Anesth Analg 112:267\u2013281. https:\/\/doi.org\/10.1213\/ANE.0b013e3182025af7","journal-title":"Anesth Analg"},{"key":"2653_CR15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/BF03016588","volume":"48","author":"J Sasao","year":"2001","unstructured":"Sasao J, Tarver SD, Kindscher JD, Taneyama C, Benson KT, Goto H (2001) In rabbits, landiolol, a new ultra-short-acting \u03b2-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol. Can J Anaesth 48:985\u2013989. https:\/\/doi.org\/10.1007\/BF03016588","journal-title":"Can J Anaesth"},{"key":"2653_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/00005344-199907000-00012","volume":"34","author":"A Sugiyama","year":"1999","unstructured":"Sugiyama A, Takahara A, Hashimoto K (1999) Electrophysiologic, cardiohemodynamic and \u03b2-blocking actions of a new ultra-short-acting \u03b2-blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol. J Cardiovasc Pharmacol 34:70\u201377. https:\/\/doi.org\/10.1097\/00005344-199907000-00012","journal-title":"J Cardiovasc Pharmacol"},{"key":"2653_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jtcvs.2007.09.086","volume":"136","author":"S Tabbutt","year":"2008","unstructured":"Tabbutt S, Nicolson SC, Adamson PC, Zhang X, Hoffman ML, Wells W, Backer CL, McGowan FX, Tweddell JS, Bokesch P, Schreiner M (2008) The safety, efficacy, and pharmacokinetics of esmolol for blood pressure control immediately after repair of coarctation of the aorta in infants and children: a multicenter, double-blind, randomized trial. J Thorac Cardiovasc Surg 136:321\u2013328. https:\/\/doi.org\/10.1016\/j.jtcvs.2007.09.086","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2653_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/FJC.0000000000000554","volume":"71","author":"G Krumpl","year":"2018","unstructured":"Krumpl G, Ul\u010d I, Trebs M, Kadlecov\u00e1 P, Hodisch J, Maurer G, Husch B (2018) Pharmacokinetics and pharmacodynamics of low-, intermediate-, and high-dose landiolol and esmolol during long-term infusion in healthy whites. J Cardiovasc Pharmacol 71:137\u2013146. https:\/\/doi.org\/10.1097\/FJC.0000000000000554","journal-title":"J Cardiovasc Pharmacol"},{"key":"2653_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0022-3476(05)81055-8","volume":"119","author":"MD Trippel","year":"1991","unstructured":"Trippel MD, Wiest DB, Gillette PC (1991) Cardiovascular and antiarrhythmic effects of esmolol in children. J Pediatr 119:142\u2013147. https:\/\/doi.org\/10.1016\/S0022-3476(05)81055-8","journal-title":"J Pediatr"},{"key":"2653_CR20","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00431-017-2969-x","volume":"176","author":"A Entenmann","year":"2017","unstructured":"Entenmann A, Michel M, Herberg U, Haas N, Kumpf M, Gass M, Egender F, Gebauer R (2017) Management of postoperative junctional ectopic tachycardia in pediatric patients: a survey of 30 centers in Germany, Austria, and Switzerland. Eur J Pediatr 176:1217\u20131226. https:\/\/doi.org\/10.1007\/s00431-017-2969-x","journal-title":"Eur J Pediatr"},{"key":"2653_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/s0735-1097(01)01773-9","volume":"39","author":"JF Price","year":"2002","unstructured":"Price JF, Kertesz NJ, Snyder CS, Friedman RA, Fenrich AL (2002) Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children <1 year of age. J Am Coll Cardiol 39:517\u2013520. https:\/\/doi.org\/10.1016\/s0735-1097(01)01773-9","journal-title":"J Am Coll Cardiol"},{"key":"2653_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0735-1097(89)90070-3","volume":"14","author":"JC Perry","year":"1989","unstructured":"Perry JC, McQuinn RL, Smith RT, Gothing C, Fredell P, Garson A (1989) Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. J Am Coll Cardiol 14:185\u2013191. https:\/\/doi.org\/10.1016\/0735-1097(89)90070-3 (discussion 192)","journal-title":"J Am Coll Cardiol"},{"key":"2653_CR23","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/0002-8703(92)90081-6","volume":"124","author":"JC Perry","year":"1992","unstructured":"Perry JC, Garson A Jr (1992) Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. Am Heart J 124:1614\u20131621. https:\/\/doi.org\/10.1016\/0002-8703(92)90081-6","journal-title":"Am Heart J"},{"key":"2653_CR24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/0735-1097(95)00268-3","volume":"26","author":"JP Pfammatter","year":"1995","unstructured":"Pfammatter JP, Paul T, Lehmann C, Kallfelz HC (1995) Efficacy and proarrhythmia of oral sotalol in pediatric patients. J Am Coll Cardiol 26:1002\u20131007. https:\/\/doi.org\/10.1016\/0735-1097(95)00268-3","journal-title":"J Am Coll Cardiol"},{"key":"2653_CR25","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/0735-1097(91)90586-x","volume":"18","author":"FA Fish","year":"1991","unstructured":"Fish FA, Gillette PC, Benson DW Jr (1991) Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group. J Am Coll Cardiol 18:356\u2013365. https:\/\/doi.org\/10.1016\/0735-1097(91)90586-x","journal-title":"J Am Coll Cardiol"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-021-02653-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00246-021-02653-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-021-02653-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T11:10:09Z","timestamp":1635592209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00246-021-02653-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2653"],"URL":"https:\/\/doi.org\/10.1007\/s00246-021-02653-7","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"5 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors assert that all procedures contributing to this work comply with the ethical standards of the Ethical Guidelines for Medical and Health Research Involving Human Subjects and with the Helsinki Declaration of 1975, as revised in 2008, and has been approved by The Institutional Review Board of the Osaka Medical College (2020-039).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained via opt-out due to the retrospective nature of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}